Assessing the Potential of Mainstream Pregnancy-Associated plasma protein A (PAPP-A) Level in Men as a Biomarker for Fertility: A review
DOI:
https://doi.org/10.56714/bjrs.50.2.7Keywords:
PAPP-A, Male fertility, Sperm quality, Predictive biomarker, Reproductive disordersAbstract
Background As a measure of a man's fertility, PAPP-A levels have lately been in the spotlight. Although most studies have focused on its role in pregnancy issues such low birth weight and gestational age, its potential impact on male fertility is starting to get more attention. Aim to determine if it is possible to use the levels of pregnancy-associated plasma protein-A (PAPP-A) in men's blood as a biomarker. The study's goal is to learn more about these levels' prognostic power and clinical assessment use by looking at the correlation with reproductive indices. Results Although there is a lack of evidence linking PAPP-A to sperm quality, there is some evidence that PAPP-A levels are associated with male reproductive problems. Future studies should look at the possibility of a stronger link between PAPP-A and male infertility. As a predictive biomarker, PAPP-A has a number of limitations when compared to other, more established fertility indicators like VAP-1. To summarize more study is needed to establish the reliability and therapeutic value of PAPP-A, while preliminary results indicate its promise as a biomarker for male fertility prediction. It will be vital to this effort to understand the possible pathways that link PAPP-A to male fertility. So, it's necessary to dig more into the link between PAPP-A levels and male infertility. As a conclusion: PAPP-A levels must be compared to other biomarkers to predict male fertility
Downloads
References
I. Kirkegaard, N. Uldbjerg, and C. Oxvig, “Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview,” Acta Obstet. Gynecol. Scand., vol. 89, no. 9, pp. 1118–1125, 2010.Doi: https://doi.org/10.1016/j.tjog.2015.12.007.
R. Rojas-Rodriguez et al., “PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against gestational diabetes in mice and humans,” Sci. Transl. Med., vol. 12, no. 571, p. eaay4145, 2020.Doi:https://doi: 10.1126/scitranslmed. aay4145.
M. T. Overgaard et al., “Complex of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: disulfide structure and carbohydrate attachment sites,” J. Biol. Chem., vol. 278, no. 4, pp. 2106–2117, 2003. Doi; http://doi.: 10.1074/jbc.M208777200..
V. Barrios et al., “Pregnancy-associated plasma protein (PAPP)-A2 in physiology and disease,” Cells, vol. 10, no. 12, p. 3576, 2021.Doi: http://doi: 10.3390/cells10123576.
Y. Yoshimura, “Insulin‐like growth factors and their binding proteins: Potential relevance to reproductive physiology,” Reprod. Med. Biol., vol. 2, no. 1, pp. 1–24, 2003. Doi: https://doi.org/10.1046%2Fj.1445-5781.2003.00016.x.
Y.-B. Wang et al., “ATP5D is a potential biomarker for male fertility,” Oxid. Med. Cell. Longev., vol. 2023, no. 1, p. 4923614, 2023. Doi: http://dx.doi.org/10.1155/2023/4923614.
C. A. Conover and C. Oxvig, “The pregnancy-associated plasma protein-A (PAPP-A) story,” Endocr. Rev., vol. 44, no. 6, pp. 1012–1028, 2023. Doi: https://doi.org/10.1210/endrev/bnad017.
C. Heeschen et al., “Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis,” J. Am. Coll. Cardiol., vol. 45, no. 2, pp. 229–237, 2005. Doi: https://doi.org/10.1016/j.jacc.2004.09.060.
M. Barati, M. Zargar, and B. Asan, “Comparison of First-Trimester Screening Biomarkers in Spontaneous (Natural) and In Vitro Fertilization Pregnancies.,” Crescent J. Med. Biol. Sci., vol. 9, no. 2, 2022. Doi: http://dx.doi.org/10.34172/cjmb.2022.19.
N. Kumar and N. K. Singh, “Emerging role of novel seminal plasma bio-markers in Male infertility: a review,” Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 253, pp. 170–179, 2020.Doi: https://doi.org/10.1210/endrev/bnad017.
Z. O. Yousif and L. A. Salih, “Study the Level of the Pregnancy Associated Plasma Protein-A (PAPP-A) Isolated from Mature Retrieved Oocyte during ICSI Protocol in Iraqi Infertile women,” Egypt. J. Hosp. Med., vol. 90, no. 1, pp. 1467–1471, 2023. Doi: https://doi.org/10.1016/j.ejogrb.2020.08.015.
B. Wahid, H. Bashir, M. Bilal, K. Wahid, and A. Sumrin, “Developing a deeper insight into reproductive biomarkers,” Clin. Exp. Reprod. Med., vol. 44, no. 4, p. 159, 2017. Doi: https://doi.org/10.21608/ejhm.2023.282370.
C. Oxvig, “The role of PAPP-A in the IGF system: location, location, location,” J. Cell Commun. Signal., vol. 9, pp. 177–187, 2015. Doi: https://doi.org/10.5653%2Fcerm.2017.44.4.159.
C. Oxvig and C. A. Conover, “The Stanniocalcin-PAPP-A-IGFBP-IGF Axis,” J. Clin. Endocrinol. Metab., vol. 108, no. 7, pp. 1624–1633, 2023. Doi: https://doi.org/10.7554%2FeLife.52322.
E. Anckaert, J. Schiettecatte, E. Sleurs, P. Devroey, and J. Smitz, “First trimester screening for Down’s syndrome after assisted reproductive technology: non-male factor infertility is associated with elevated free beta-human chorionic gonadotropin levels at 10–14 weeks of gestation,” Fertil. Steril., vol. 90, no. 4, pp. 1206–1210, 2008. Doi: https://doi.org/10.1210/clinem/dgad053.
M. Movahedi, S. Khanjani, Z. Shahshahan, M. Hajihashemi, F. Farahbod, and E. Shahsavandi, “Evaluation of the relationship between pregnancy-associated plasma protein A (PAPP-A) and pregnancy outcomes,” Adv. Biomed. Res., vol. 12, no. 1, p. 91, 2023.Doi: https://doi.org/10.1016/j.fertnstert.2007.08.050.
P. Prithviraj et al., “Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes,” Sci. Rep., vol. 10, no. 1, p. 13779, 2020.Doi: https://doi: 10.4103/abr.abr_344_21.
E. C. Jenkins, S. O. Brown, and D. Germain, “The multi-faced role of PAPP-A in post-partum breast cancer: IGF-signaling is only the beginning,” J. Mammary Gland Biol. Neoplasia, vol. 25, pp. 181–189, 2020. Doi: https://doi.org/10.1038/s41598-020-70774-9.
S. L. Harstad and C. A. Conover, “Tissue-specific changes in pregnancy associated plasma protein-A expression with age in mice,” Exp. Gerontol., vol. 57, pp. 13–17, 2014.
Doi: https://doi.org/10.1186%2Fs12929-024-01012-x
A. Kumar, T. B. Sridharn, and K. A. Rao, “Role of seminal plasma proteins in effective zygote formation-A success road to pregnancy,” Protein Pept. Lett., vol. 26, no. 4, pp. 238–250, 2019. Doi: https://doi.org/10.1016/j.exger.2014.04.011.
M. Mohrin et al., “Inhibition of longevity regulator PAPP‐A modulates tissue homeostasis via restraint of mesenchymal stromal cells,” Aging Cell, vol. 20, no. 3, p. e13313, 2021. Doi: https://doi.org/10.2174/0929866526666190208112152.
N. Tarban et al., “Loss of adenosine A3 receptors accelerates skeletal muscle regeneration in mice following cardiotoxin-induced injury,” Cell Death Dis., vol. 14, no. 10, p. 706, 2023. Doi; https://doi.org/10.1111/acel.13313.
R. Hjortebjerg, D. A. Pedersen, J. Mengel-From, L. H. Jørgensen, K. Christensen, and J. Frystyk, “Heritability and circulating concentrations of pregnancy-associated plasma protein-A and stanniocalcin-2 in elderly monozygotic and dizygotic twins,” Front. Endocrinol. (Lausanne)., vol. 14, p. 1193742, 2023. Doi: https://doi.org/10.3389/fendo.2023.1193742.
J. K. Christians, N. Amiri, J. D. Schipilow, S. W. Zhang, and K. I. May-Rashke, “Pappa2 deletion has sex-and age-specific effects on bone in mice,” Growth Horm. IGF Res., vol. 44, pp. 6–10, 2019. Doi: https://doi.org/10.3389/fendo.2023.1193742.
Y. Li, C. Zhou, X. Zhou, L. Song, and R. Hui, “PAPP-A in cardiac and non-cardiac conditions,” Clin. Chim. acta, vol. 417, pp. 67–72, 2013. Doi: https://doi.org/10.1016/j.ghir.2018.10.006.
K. Kalantar-Zadeh, T. H. Jafar, D. Nitsch, B. L. Neuen, and V. Perkovic, “Chronic kidney disease,” Lancet, vol. 398, no. 10302, pp. 786–802, 2021. Doi: https://doi.org/10.1016/j.cca.2012.12.006.
H. G. Bone et al., “10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension,” lancet Diabetes Endocrinol., vol. 5, no. 7, pp. 513–523, 2017. Doi: https://doi.org/10.5114%2Faoms.2020.91283.
L. A. Bach, “40 years of IGF1: IGF-binding proteins,” J. Mol. Endocrinol., vol. 61, no. 1, pp. T11–T28, 2018. Doi: http://doi: 10.1016/S2213-8587(17)30138-9.
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt, “The role of the IGF system in cancer growth and metastasis: overview and recent insights,” Endocr. Rev., vol. 28, no. 1, pp. 20–47, 2007. Doi: https://doi.org/10.1530/JME-18-0056.
J. Dereke, C. Nilsson, H. Strevens, M. Landin‐Olsson, and M. Hillman, “Pregnancy‐associated plasma protein‐A2 levels are increased in early‐pregnancy gestational diabetes: a novel biomarker for early risk estimation,” Diabet. Med., vol. 37, no. 1, pp. 131–137, 2020. Doi: https://doi.org/10.1111/dme.14088.
A. Vashisht and G. K. Gahlay, “Understanding seminal plasma in male infertility: emerging markers and their implications,” Andrology, vol. 12, no. 5, pp. 1058–1077, 2024. Doi: https://doi.org/10.1111/andr.13563.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Basrah Researches Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
